Multi-Fc Therapeutic Dosing via iC3b Biomarker Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining an effective dose of multi-Fc therapeutics for treating autoimmune and inflammatory diseases lack precision, leading to inadequate treatment responses in some patients and potential adverse effects from excessive dosing.
Innovation Solution
The method involves determining a patient's response to a multi-Fc therapeutic by measuring circulating levels of inactivated C3b (iC3b) and adjusting the dose based on these levels, with cumulative escalated doses administered until a predetermined iC3b threshold is met or a significant change in iC3b levels is observed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fixed dosing schedules are used for multi-Fc therapeutics, then treatment administration is simplified, but treatment response varies and precision is lost
Solution Approach 1:
The patent implements dynamic dose adjustment based on real-time measurement of iC3b levels in patient blood samples. The dosing schedule transitions from fixed to variable, with dose amounts modified according to individual patient response and measured complement levels, enabling precision medicine while maintaining operational feasibility through standardized monitoring protocols
Solution Approach 2:
The invention establishes a feedback loop where patient blood samples are measured for iC3b levels, and these measurements directly inform subsequent dosing decisions. The system continuously monitors treatment response and adjusts future doses based on observed changes in complement levels, creating a closed-loop control system that optimizes therapeutic effectiveness
2Reliability
If higher doses of multi-Fc therapeutic are administered, then therapeutic efficacy is improved, but adverse side effects increase
Solution Approach 1:
The patent uses iC3b concentration levels as a critical parameter to guide dose adjustments. By monitoring changes in this specific complement level, the system identifies the optimal dose range that achieves therapeutic efficacy while avoiding excessive dosing that would cause adverse effects, allowing continuous optimization of the therapeutic index
Solution Approach 2:
The invention replaces traditional empirical dose escalation approaches with a biochemical monitoring system based on complement level measurement. This substitution of mechanical/experiential dosing with molecular/biochemical guidance enables more precise control of therapeutic effects and minimizes harmful side effects through objective, quantifiable metrics
3Measurement precision
If multiple blood samples are drawn for monitoring, then treatment response is accurately assessed, but patient inconvenience and test complexity increase
Solution Approach 1:
The patent positions iC3b measurement as a universal marker that serves multiple functions: assessing treatment response, guiding dose adjustments, monitoring complement activation, and evaluating therapeutic efficacy. This single biomarker replaces the need for multiple complex monitoring parameters and diverse assay types, simplifying the overall monitoring protocol while maintaining comprehensive assessment capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the optimization of therapeutic effects while minimizing adverse side effects by ensuring that patients receive the maximally effective dose of the multi-Fc therapeutic, as indicated by increased iC3b levels.
Implementation Method 1
The methods are based, at least in part, on the unexpected findings that levels of iC3b correlate with the in vitro efficacy of a multi-Fc therapeutic
Data Source
AI summary
The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics. The present invention further provides for improvements in the use of such multi-Fc therapeutics in the treatment of autoimmune and inflammatory diseases.